HDAC inhibitors affect cellular metabolic pathways ... and their ability to cross the blood–brain barrier. Histone deacetylases (HDACs) — enzymes that affect the acetylation status of histones ...

Histone deacetylase inhibitors (HDACi) are a new class of chemotherapeutic agents that have histone and nonhistone targets and have demonstrated potent anticancer activities in preclinical in ...

Abexinostat, an HDAC2 inhibitor, restores chromatin AC ... supporting its role in RCC pathophysiology. AC, acetylation; HDAC2, histone deacetylase 2; HIF-α, hypoxia-inducible factor 1-alpha; RCC, ...

entinostat—a histone deacetylase inhibitor (HDACi). The combination was studied in a group of 27 patients with advanced PDA who had previously been treated with chemotherapy. In a small subset ...

Research on the biological basis of addiction has found that the critical epigenetic enzyme histone deacetylase 5 (HDAC5) limits the expression of the gene Scn4b, regulating neuronal activity and ...

The current notice periods for Directors are 3 months for the Chairman, 1 month for non-executive Directors and six months for Stephen Stamp. The Group has no specific policy on loss of office other ...

Augustine’s approach focuses on inhibiting the cytosolic histone deacetylase 6 (HDAC6 ... to further develop two discovery-stage HDAC6 inhibitors targeting “peripherally restricted and ...

Eight months after announcing the $18.5 million first tranche of its series A, Augustine Therapeutics has closed the oversubscribed round at $85 million and is now ready to begin clinical development ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...